Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Other Non Operating Income (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Other Non Operating Income for 5 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 78.44% year-over-year to $1.5 million, compared with a TTM value of $3.1 million through Dec 2025, up 27.77%, and an annual FY2025 reading of $3.1 million, up 27.77% over the prior year.
  • Other Non Operating Income was $1.5 million for Q4 2025 at SAB Biotherapeutics, up from $765881.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $7.8 million in Q1 2022 and bottomed at -$9.4 million in Q4 2022.
  • Average Other Non Operating Income over 5 years is $357675.9, with a median of $510878.5 recorded in 2024.
  • The sharpest move saw Other Non Operating Income plummeted 1328.24% in 2022, then surged 6264.31% in 2023.
  • Year by year, Other Non Operating Income stood at -$660108.0 in 2021, then tumbled by 1328.24% to -$9.4 million in 2022, then soared by 101.03% to $97183.0 in 2023, then skyrocketed by 779.78% to $854997.0 in 2024, then skyrocketed by 78.44% to $1.5 million in 2025.
  • Business Quant data shows Other Non Operating Income for SABS at $1.5 million in Q4 2025, $765881.0 in Q3 2025, and $295630.0 in Q2 2025.